Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shree Ganesh Biotech has filed a quarterly compliance statement with BSE, Calcutta Stock Exchange, and MSEI under SEBI LODR Regulation 32(1). The company has confirmed that it has no unutilized funds remaining as on 30 June 2025 (or the date of filing) from any past public issue, rights issue, preferential issue, or qualified institutional placement (QIP). Consequently, no Annexure-A detailing deviations has been submitted. The letter is signed by Wholetime Director Aman Patel on 25 July 2025. This is a routine, NIL-compliance disclosure, not a fund-raising announcement.
This is a routine NIL compliance filing with no material financial impact on the stock. It essentially signals that there are no outstanding proceeds from prior issues requiring monitoring — a neutral disclosure for shareholders.